You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
West Pharmaceutical Services raised 2026 revenue guidance to $3.41 to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48, after Q3 revenue of $874 million and adjusted EPS of $2.66.
West Pharmaceutical Services Inc reported nine-month 2026 net sales of $2,591.7 million, up 14.2%, and operating profit of $623.6 million, up 45.6%; Proprietary Products drove growth, while West Vantage organic sales declined 0.2%.
West Pharmaceutical Services, Inc. reported third-quarter net sales of $874.5 million, up 8.7%, and adjusted-diluted EPS of $2.66, up 35.7%. It raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance to $9.38 to $9.48.
West Pharmaceutical Services, Inc. entered a five-year credit agreement on October 26, 2026, providing a $750 million revolver and $200 million term loan, and repaid $130.0 million under its existing agreement without early termination penalties.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. West delivered strong Q3 results, with organic sales growth of 11.9%, adjusted EPS growth of 35.7%, expanded margins, and 20.3% organic growth in HVP Components; full-year sales and adjusted EPS guidance were raised. West Vantage, generics, year-to-date free cash flow, the SmartDose divestiture, Q4 foreign-exchange pressure, and West Bandage gross margin were offsets or risks.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted EPS non-GAAP | $2.37 | Three months ended June 30, 2026 filing | — |
| Adjusted net income non-GAAP | $169.4M | Three months ended June 30, 2026 filing | — |
| Adjusted operating profit non-GAAP | $197.4M | Three months ended June 30, 2026 filing | — |
| Consolidated net sales organic growth non-GAAP | 12.7% | Three Months Ended June 30, 2026 filing | — |
| Proprietary Products net sales organic growth non-GAAP | 15.5% | Three Months Ended June 30, 2026 filing | — |
| West Vantage net sales organic growth non-GAAP | 0.8% | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WST
this stock
West Pharmaceutical Services Inc
|
$29.01B | +51.3% | +2.0% | 46.7 | 2.6% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
West Pharmaceutical Services, Inc. reported third-quarter net sales of $874.5 million, up 8.7%, and adjusted-diluted EPS of $2.66, up 35.7%. It raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance to $9.38 to $9.48.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WST | +4.2% | +8.4% | +31.7% | +0.9% | +51.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +1.6% | +9.6% | +31.2% | +1.1% | +40.7% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
